Skip to main content

Table 1 Summary of the FDA approved monoclonal antibodies for treatment of solid tumors

From: State of the art in anti-cancer mAbs

mAB Name Type Target FDA approveda
Trastuzumab Herceptin® Humanized HER2 HER2-positive metastatic/non-metastatic breast cancer
HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma
Pertuzumab Perjeta® Humanized HER2 HER2-positive metastatic breast cancer
HER2-positive, locally advanced, inflammatory, or early stage breast cancer
Cetuximab Erbitux® Chimeric EGFR Metastatic CRC
HNSCC
Panitumumab Vectibix® Human EGFR Metastatic CRC
Necitumumab Portrazza™ Human EGFR Metastatic squamous NSCLC
Dinutuximab Unituxin™ Chimeric GD2 Pediatric high risk neuroblastoma
Bevacizumab Avastin® Humanized VEGF-A Metastatic CRC
Recurrent or metastatic non-squamous NSCLC
HER2-negative metastatic breast cancer (revoked in 2011)
Metastatic renal cell carcinoma
Persistent, recurrent or metastatic cervical cancer
Glioblastoma
Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Ramucirumab Ciramza® Human VEGFR-2 Advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
Metastatic NSCLC
Metastatic CRC
Olaratumab Lartruvo® Human PDGFR-α Soft tissue sarcoma
Ipilimumab Yervoy® Human CTLA-4 Unresectable or metastatic melanoma
Cutaneous melanoma
Nivolumab Opdivo® Human PD-1 Unresectable or metastatic melanoma
Metastatic squamous NSCLC
Metastatic NSCLC
Advanced RCC
Recurrent or metastatic HNSCC
Pembrolizumab Keytruda® Humanized PD-1 Unresectable or metastatic melanoma
Metastatic NSCLC
Recurrent or metastatic HNSCC
Atezolizumab Tecentriq™ Humanized PD-L1 Locally advanced or metastatic urothelial carcinoma
Metastatic NSCLC
Ado-trastuzumab emtansineb Kadcyla® Humanized HER2 HER2-positive metastatic breast cancer
Denosumab Xgeva® Human RANKL Bone metastases from solid tumors
  1. CRC colorectal cancer, HNSCC head & neck squamous cell carcinoma, NSCLC non-small cell lung cancer, RCC renal cell carcinoma
  2. aSee the text for further details
  3. bTrastuzumab covalently linked to emtansine (DM1)